Status:
COMPLETED
Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Spontaneous Bacterial Peritonitis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
1. All consecutive patients with Cirrhosis and ascites admitted to ILBS (Institute of Liver \& Biliary Sciences) will be evaluated for the presence of SBP (Spontaneous Bacterial Peritonitis) by asciti...
Detailed Description
Baseline evaluation: Baseline clinical, laboratory and disease severity parameters will be evaluated for each study patient. 1. Etiology of cirrhosis. 2. Severity of liver disease. CTP (Child-Turcot...
Eligibility Criteria
Inclusion
- \- Cirrhotic Patients with SBP (Spontaneous Bacterial Peritonitis) having any of the following risk factors would be considered as 'Difficult to Treat SBP' and would be included -
- Nosocomial SBP: occurence of SBP (Spontaneous Bacterial Peritonitis) after 48 hours of hospital admission, or
- Prior ascitic fluid infection with 3rd generation cephalosporin resistant organism, or
- No response to treatment with 3rd generation cephalosporins after 48 hours.
Exclusion
- Age less than 18 years.
- Cirrhotics with SBP (Spontaneous Bacterial Peritonitis) managed as outpatients.
- Post liver transplant, HIV patients.
- Patients on systemic chemotherapy, immunosuppressant drugs.
- Growth of bacteria resistant to intervention drugs in ascitic fluid culture.
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT01852630
Start Date
December 1 2012
End Date
December 1 2015
Last Update
November 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences (ILBS)
New Delhi, National Capital Territory of Delhi, India, 110070